Publications by authors named "Barbara Jenko"
Article Synopsis
- Metabolic syndrome is a significant global health issue, and identifying early signs can help implement preventive lifestyle changes.
- A study involving 103 young, healthy adults assessed various indicators, revealing that those at higher risk for metabolic syndrome had concerning body metrics and lower physical activity levels.
- Simple measurements and assessments can effectively identify individuals at risk, allowing for early interventions that could enhance health outcomes and reduce long-term healthcare costs.
Background: Methotrexate is the most frequently administered first-line treatment for rheumatoid arthritis (RA). The disease-modifying effects of methotrexate are mainly associated with enhanced release of free adenosine. The downstream anti-inflammatory effects of adenosine are mediated via its binding to adenosine receptor 2A (ADORA2A) and 3 (ADORA3).
View Article and Find Full Text PDFMethotrexate (MTX) is the first line treatment for rheumatoid arthritis (RA), but nevertheless 30% of patients experience MTX inefficacy. Our aim was to develop a clinical pharmacogenetic model to predict which RA patients will not respond to MTX monotherapy. We also assessed whether this model can be generalized to other populations by validating it on a group of Serbian RA patients.
View Article and Find Full Text PDFBackground: The activation of NLRP3-inflammasome may contribute to inflammatory processes in rheumatoid arthritis (RA). Functional polymorphisms in the genes coding for its components NLRP3 and CARD8 were associated with a proinflammatory phenotype. Our aim was to investigate the influence of these polymorphisms on RA susceptibility and disease activity at the time of diagnosis and after six months of treatment.
View Article and Find Full Text PDFAim: Survivin expression was associated with unfavorable and erosive course of rheumatoid arthritis (RA). This is the first study investigating association between BIRC5 polymorphisms, survivin plasma levels and disease activity in RA.
Patients & Methods: A testing group of 123 and validation group of 150 RA patients initially treated with methotrexate monotherapy were genotyped for three BIRC5 promoter polymorphisms.